Key Highlights

  • Jack Henry & Associates (NASDAQ:JKHY) closed the October 13, 2026 session at USD 153.08 with a 0.017% golden cross while about 2.1% below both averages; fiscal 2026 revenue rose 7.1% and fiscal 2027 GAAP EPS guidance is USD 7.33 to USD 7.38.
  • ResMed (NYSE:RMD) closed at USD 235.04 with a 0.423% golden cross and price about 4.0% above its 50-day average; fiscal fourth-quarter revenue rose 9% to USD 1.46 billion and results are due October 29, 2026.
  • Broadridge Financial Solutions (NYSE:BR) closed at USD 168.44 with a 0.448% golden cross while price sat about 0.7% below its 50-day average; fiscal 2026 recurring revenue rose 8% and the annual dividend rose 12% to USD 4.36.
  • A golden cross means the 50-day average has risen above the 200-day average; it lags price, and gaps below 0.5% are closer to ties than to trend changes, so each company's operating data matter more.

Jack Henry & Associates (NASDAQ:JKHY): Golden cross below both averages

A golden cross occurs when the 50-day average rises above the 200-day average. Here USD 156.37 is above USD 156.34, a 0.017% gap, effectively a tie. The label sounds bullish, yet the shares at USD 153.08 were about 2.1% below both averages, simple arithmetic on published numbers. Averages lag price, so a golden cross can appear after a recovery has stalled. The 2.31% gain on October 13 had no stated company catalyst. A cross this narrow can flip back within a session, so it is not evidence of a new uptrend on its own. The setup resembles a stock that has bounced inside a range and not one that has broken out. Jack Henry & Associates (NASDAQ:JKHY) supplies core processing and digital banking software to community banks and credit unions. Fiscal 2026 GAAP revenue was USD 2,544.3 million, up 7.1%, with diluted EPS of USD 6.98, up 11.9%, and free cash flow of USD 539.3 million. Fourth-quarter operating margin compressed to 21.2% from 25.3%, which the company partly attributed to higher personnel costs, and fourth-quarter diluted EPS fell 10.2% to USD 1.57. Chief executive Greg Adelson cited 58 competitive core wins. Cash fell to USD 12.1 million from USD 102.0 million and credit facility debt rose to USD 40 million, reflecting buybacks of USD 448 million over the year. Margin is the main question: guidance of 24.5% to 24.7% for fiscal 2027 requires recovery from the fourth-quarter 21.2%. Bank technology spending, contract renewals with community banks and integration of the Victor acquisition, whose first anniversary is September 30, all matter. From October 1 its revenue counts in organic growth. The fiscal first-quarter report is expected in early November, though the date has not been confirmed.

ResMed (NYSE:RMD): Golden cross with price above

A golden cross means the 50-day average of USD 226.06 has risen above the 200-day average of USD 225.10, a gap of 0.423%. The shares at USD 235.04 were about 4.0% above the 50-day and 4.4% above the 200-day average, simple arithmetic on published numbers, so price and averages agree. Averages lag price, so a cross usually appears after a recovery is under way and can precede either continued gains or a fade. The 0.19% gain on October 13 had no stated company catalyst, and the cross itself says nothing about future returns. A gap of 0.423% is still modest. ResMed (NYSE:RMD) makes devices for sleep apnea and respiratory care. Fiscal 2026 revenue was USD 5.7 billion, up 10%, with free cash flow of USD 1.6 billion. In the fourth quarter GAAP diluted EPS was USD 2.64, up 2%, while non-GAAP EPS of USD 2.95 excluded items such as the Astral field safety notification. Shareholders received USD 287 million in the quarter, including USD 200 million of buybacks, and the board raised the quarterly dividend 10% to USD 0.66, payable September 24. The company agreed to sell MatrixCare, expected to close in the first quarter of fiscal 2027, and completed the acquisition of Noctrix Health. The difference between GAAP and non-GAAP margin shows the cost of the Astral safety action, and further recall costs are a risk. Competition, reimbursement pressure and changes in how sleep apnea is treated, are standard sector risks. The first-quarter report on October 29 should show whether the 62.3% non-GAAP gross margin holds. The release gave no specific revenue guidance, and the dividend and buyback plan are intentions, not guarantees.

Broadridge Financial Solutions (NYSE:BR): Golden cross near the averages

The 50-day average of USD 169.62 is above the 200-day average of USD 168.87, a gap of 0.448%. The shares at USD 168.44 were about 0.7% below the 50-day and 0.3% below the 200-day average, simple arithmetic on published numbers, so price sits just under both lines even as the label is bullish. Averages lag price, and the crossover reflects a recovery already seen. The 1.22% gain on October 13 had no stated company catalyst. A golden cross this thin is closer to a tie than a trend change, and it can reverse with a small move in price. Moving averages weigh every session equally, so the cross can change as older prices drop out of the window. Broadridge Financial Solutions (NYSE:BR) processes proxy votes and investor communications and supplies trading and wealth technology. Fiscal 2026 revenue rose 9% to USD 7,477 million, recurring revenue rose 8% to USD 4,878 million and adjusted EPS rose 12% to USD 9.60. Free cash flow was USD 1,233 million, 110% of earnings. Fourth-quarter closed sales rose 39% to USD 158 million. Acquisitions during the year, including Acolin, iJoin, Signal, CQG and Kyndryl's Securities Industry Services business, used USD 282.7 million of cash. Adjusted EPS excludes non-cash digital asset gains of USD 227 million, so reported earnings differ from the adjusted figures. Recurring revenue is the steadier base because it comes from multi-year client contracts. Recurring revenue depends on retaining large bank and broker clients, and proxy volumes vary with the market cycle and shareholder voting activity.

Where Things Stand

The answer is that the three crosses show recoveries in progress, not confirmed uptrends. ResMed (NYSE:RMD) has price above both averages, which supports the signal. Jack Henry & Associates (NASDAQ:JKHY) has price below both, which weakens it. Broadridge Financial Solutions (NYSE:BR) sits just under both lines. Operating data are the stronger evidence. ResMed (NYSE:RMD) reports October 29, and Jack Henry and Broadridge are expected in early November. This is not investment advice.